|
Quantamental
Equity Research on AUROBINDO PHARMA LTD | Release: 19 Feb 2019 16:36:48
UTC+05:30 | Reporting Currency: INR | Trading Currency: INR |
Exchange:NSE/BSE NSE CODE:AUROPHARMA and BSE CODE:524804 |
Last Close: |
INR 722.6 |
Fair Value: |
INR 762.3 |
Est. Price by Mar 19: |
INR 839.05 |
Market Capitalization (INR
Crs): |
42337.68 |
Industry: |
Pharmaceuticals |
Rating: |
BUY |
Upside: |
16% |
Company Profile |
|
|
Aurobindo Pharma is engaged in manufacturing and marketing of
active pharmaceutical ingredients, generic pharmaceuticals and related
services. |
Growth Per Share |
|
|
Particulars |
1-Year |
3-Year |
5-Year |
|
Revenue % |
10% |
66% |
190% |
|
EBIT % |
6% |
43% |
418% |
|
Earnings % |
5% |
54% |
725% |
|
Book Value
% |
25% |
127% |
348% |
|
Stock Total
Return % |
-5% |
-6% |
610% |
|
|
Share holding
pattern |
Particulars |
%age |
|
(A) Promoter
& Promoter Group |
51.87 |
|
(B) FII/FPI |
20.07 |
|
(C)
DII/Insurance Companies |
14.44 |
|
(D) Public holding < 2 lakhs of cap. |
6.51 |
|
(E) Others |
7.11 |
|
Grand Total |
100.00 |
|
|
Fundamentals
(Historical and Estimated) |
Particulars |
Mar-10 |
Mar-11 |
Mar-12 |
Mar-13 |
Mar-14 |
Mar-15 |
Mar-16 |
Mar-17 |
Mar-18 |
Mar-19 E |
Mar-20 E |
Mar-21 E |
Mar-22 E |
Mar-23 E |
|
Price |
94 |
98 |
62 |
87 |
279 |
658 |
764 |
648 |
617 |
839 |
955 |
1063 |
1183 |
1273 |
|
Return on
Equity |
31% |
23% |
-5% |
11% |
31% |
31% |
28% |
25% |
21% |
15% |
15% |
14% |
14% |
13% |
|
Price to
Earning |
4.7 |
5.1 |
-14.5 |
8.6 |
6.9 |
12.2 |
22.1 |
16.5 |
14.9 |
24.2 |
24.2 |
24.2 |
24.2 |
24.2 |
|
EVTI |
1.3 |
1.2 |
1.1 |
1.0 |
1.5 |
1.9 |
3.6 |
2.7 |
2.5 |
2.8 |
2.8 |
2.7 |
2.7 |
2.7 |
|
EVTIFM |
4.7 |
5.1 |
-14.5 |
8.6 |
6.9 |
12.2 |
22.1 |
16.5 |
14.9 |
24.2 |
24.2 |
24.2 |
24.2 |
24.2 |
|
Price to Book
Value |
1.4 |
1.2 |
0.8 |
1.0 |
2.2 |
3.7 |
6.1 |
4.0 |
3.1 |
3.6 |
3.6 |
3.4 |
3.3 |
3.1 |
|
Debt to
Equity |
1.2 |
1.0 |
1.3 |
1.3 |
1.0 |
0.9 |
0.7 |
0.4 |
0.4 |
0.3 |
0.2 |
0.1 |
0.0 |
0.0 |
|
Dividend
Yield |
1% |
2% |
2% |
2% |
1% |
1% |
0% |
0% |
0% |
0% |
0% |
0% |
0% |
0% |
|
Cash Flow to
Firm |
16% |
0% |
-6% |
2% |
4% |
1% |
1% |
7% |
-1% |
2% |
3% |
5% |
6% |
6% |
|
|
Detailed
Estimates |
Title |
Mar-18 |
Mar-19 E |
Mar-20 E |
Mar-21 E |
Mar-22 E |
Mar-23 E |
|
Sales |
16,463.03 |
18,870.31 |
21,175.65 |
23,253.23 |
24,975.26 |
26,224.03 |
|
EBITDA |
3,876.87 |
3,793.40 |
4,256.83 |
4,674.47 |
5,020.64 |
5,271.67 |
|
EBIT |
3,318.90 |
3,153.84 |
3,574.22 |
3,962.35 |
4,364.72 |
4,667.52 |
|
PBT |
3,241.18 |
3,076.12 |
3,499.49 |
3,898.47 |
4,335.22 |
4,667.52 |
|
NPAT |
2,423.17 |
2,030.76 |
2,310.26 |
2,573.65 |
2,861.99 |
3,081.36 |
|
Price to
Earning |
14.91 |
24.21 |
24.21 |
24.21 |
24.21 |
24.21 |
|
Price to Book
Value |
3.09 |
3.62 |
3.55 |
3.43 |
3.32 |
3.14 |
|
Debt to
Equity |
0.41 |
0.34 |
0.25 |
0.10 |
- |
- |
|
Return on
Equity |
0.21 |
0.15 |
0.15 |
0.14 |
0.14 |
0.13 |
|
Enterprise Value to Total Income (EVTI) |
2.45 |
2.82 |
2.80 |
2.73 |
2.72 |
2.68 |
|
Enterprise Value to Total Income to Firm Margin(EVTIFM) |
16.97 |
26.75 |
26.30 |
25.42 |
24.70 |
23.92 |
|
Price or Est.
Share Prices |
616.79 |
839.05 |
954.55 |
1,063.40 |
1,182.55 |
1,273.20 |
|
|
DISCOUNTED CASH
FLOW |
Title |
Mar-19 E |
Mar-20 E |
Mar-21 E |
Mar-22 E |
Mar-23 E |
|
PBT |
3,076.12 |
3,499.49 |
3,898.47 |
4,335.22 |
4,667.52 |
|
Interest |
77.72 |
74.74 |
63.88 |
29.50 |
- |
|
Depreciation |
639.56 |
682.60 |
712.12 |
655.92 |
604.15 |
|
Cash Flow
Before Tax |
3,793.40 |
4,256.83 |
4,674.47 |
5,020.64 |
5,271.67 |
|
Tax Rate |
33.99 |
33.99 |
33.99 |
33.99 |
33.99 |
|
Cash Flow
After Tax |
2,504.02 |
2,809.93 |
3,085.62 |
3,314.13 |
3,479.83 |
|
Terminal Cash
Flow |
- |
60,539.27 |
|
Total Cash
Flow |
2,504.02 |
2,809.93 |
3,085.62 |
3,314.13 |
64,019.11 |
|
Present Value of
Cash Flow |
44,663.25 |
|
Debt |
- |
|
Value of Equity |
44,663.25 |
|
Fair Value Per
Share |
762.30 |
|
|
Equity |
|
|
|
|
42,338 |
|
Debt |
|
|
|
|
4,770 |
|
|
Beta |
Take from Reuters |
|
|
0.84 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Risk Free Rate |
Prevailing Yield in India |
|
|
7% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Market Risk Premium |
Assuming 8.82% premium
for Equity Investments |
7% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest Paid |
|
|
|
|
78 |
|
Tax Benefit |
|
|
|
|
20 |
|
Interest Net of Tax |
|
|
|
|
58 |
|
Debt |
|
|
|
|
4,770 |
|
Cost of Debt |
|
|
|
|
1% |
|
Cost of Equity |
|
|
|
|
13% |
|
Debt Weight |
|
|
|
|
10% |
|
Equity Weight |
|
|
|
|
90% |
|
WACC |
|
|
|
|
12% |
|
|
Cash Flow of Mar-23 E |
|
|
|
|
3,479.83 |
|
Growth |
|
|
|
|
6.1% |
|
Present Value of Terminal
Cashflow |
|
|
|
|
60,539.27 |
|
|
Peer Comparision |
# |
Name |
CMP
Rs. |
Mar
Cap Rs.Cr. |
B.V.
Rs. |
Annualized
ROE % |
ROCE
% |
Latest
EVTI |
Latest
EVTIFM |
CMP
/ BV |
P/E |
Debt
/ Eq |
Div
Yld % |
Growth
Rate R % |
SGR
% |
Ann
Total Income |
Unpledged
Prom Hold % |
PQEIOI |
QoQ
Sales % |
Qtr
Sales Var % |
QoQ
Profits % |
Qtr
Profit Var % |
Graham's
Number Rs. |
1 |
Sun Pharma.Inds. |
422.90 |
101,468 |
170.98 |
19.96 |
10.41 |
2.99 |
16.63 |
2.47 |
21.75 |
0.27 |
0.47 |
15.53 |
15.75 |
31,733 |
50.28 |
80 |
11.57 |
16.34 |
-1,015.32 |
310.00 |
228.82 |
2 |
Aurobindo Pharma |
722.60 |
42,338 |
221.43 |
31.16 |
22.85 |
2.14 |
15.96 |
3.26 |
18.03 |
0.41 |
0.35 |
29.28 |
26.10 |
21,244 |
50.68 |
63 |
10.91 |
21.53 |
16.48 |
22.97 |
443.00 |
3 |
Cadila Health. |
314.00 |
32,146 |
87.03 |
29.08 |
18.28 |
2.46 |
17.10 |
3.61 |
16.24 |
0.62 |
1.11 |
23.21 |
21.21 |
14,436 |
74.79 |
67 |
20.83 |
9.75 |
22.32 |
-6.00 |
194.60 |
4 |
Dr Reddy's Labs |
2,563.35 |
42,567 |
790.42 |
20.19 |
7.75 |
2.84 |
26.27 |
3.24 |
24.09 |
0.40 |
0.78 |
13.11 |
13.20 |
15,868 |
26.77 |
107 |
1.23 |
0.80 |
-3.47 |
65.28 |
1,375.98 |
5 |
Cipla |
540.55 |
43,552 |
182.97 |
11.63 |
9.64 |
2.78 |
39.01 |
2.95 |
31.40 |
0.29 |
0.55 |
9.64 |
8.93 |
16,344 |
36.68 |
172 |
-0.11 |
2.39 |
-11.89 |
-17.06 |
261.58 |
6 |
Strides Pharma |
402.15 |
3,601 |
264.06 |
65.31 |
16.15 |
1.22 |
14.08 |
1.52 |
4.20 |
1.03 |
0.50 |
63.54 |
78.58 |
4,272 |
21.89 |
180 |
8.44 |
6.10 |
-3,472.64 |
234.73 |
754.91 |
Comments
Post a Comment